How CORE-ABR grades it
No cell wall, so all beta-lactams are inactive. M. hominis is intrinsically resistant to erythromycin and azithromycin but not to clindamycin; M. genitalium macrolide resistance is common and arises from mutations most panels don't target. Treatment of M. genitalium follows CDC STI guidelines.
What the report shows for Mycoplasma hominis / genitalium
- Detected or not detected, with Ct, limit of detection and cycles above LOD — see PCR reporting.
- A short pathogen summary, including colonizer likelihood where it applies.
- A graded column on the antibiogram, and therapy options by scenario on the P.A.C.T. report.
- When not detected, it is still listed among targets tested.
Resistance genes CORE-ABR applies
When detected, each of these genes is applied to Mycoplasma hominis / genitalium only for the agents its mechanism defeats.
Tagged
Decision support only. The treating clinician decides. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting. Absence of a detected resistance gene does not establish susceptibility. Organism targets vary by panel; CORE-ABR is configured to the assay each laboratory runs.